Navigation Links
Addition of bevacizumab to initial treatment for brain tumors does not extend patients' lives
Date:6/2/2013

Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival,. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting.

Chicago, IllinoisGBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is less than 16 months and few patients live beyond five years. GBM is characterized by angiogenesisthe formation of new blood vessels that support tumor growth stimulated by the GBM-produced vascular endothelial growth factor A (VEGF-A). Bevacizumab is a monoclonal antibody that targets VEGF-A production to block the growth of tumor-derived blood vessels. "Clinical trials evaluating the addition of bevacizumab to standard treatment for recurrent glioblastoma demonstrated clinical benefit and led to the drug's FDA approval for this indication," says Mark Gilbert, MD, RTOG 0825 Principal Investigator and professor of neuro-oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas. "Additionally, compelling preclinical data suggest that anti-angiogenic targeted therapies may normalize the tumor's rapidly forming and underdeveloped blood vessels, resulting in improved oxygen and chemotherapy delivery to the tumor and potentially enhancing radiotherapy and chemotherapy treatment," explains Gilbert. The RTOG 0825 study tested this hypothesis.

Six hundred and thirty-seven adult study participants were enrolled in the multicenter trial and randomized into one of two study arms, with treating physicians blinded to treatment assignment. All participants were treated with standard radiotherapy (RT) (60 Gy) and daily temozolomide. Bevacizumab (experimental arm) or a plac
'/>"/>

Contact: Shawn Farley
PR@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
2. Warmer soils release additional CO2 into atmosphere; Effect stabilizes over longer term
3. Additional research must be done to ensure safety of pit latrines, new study says
4. Evolution Marketing Research Grows its Practice with Addition of Three Key Industry Professionals
5. New data suggests HIV superinfection rate comparable to initial HIV infection
6. NLST: CT detects twice as many lung cancers as X-ray at initial screening exam
7. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
8. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
9. Genetic research develops tools for studying diseases, improving regenerative treatment
10. Step forward in research into new treatments for brain edema
11. Marshall University study may lead to new treatments for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... hard to come by, a University of Central Florida and ... National Institutes of Health highly competitive grants for hemophilia research. ... is aimed at determining whether a green technique pioneered at ... The second grant worth $2 million for four years is ...
... The Newark College of Engineering (NCE) at NJIT has been ... one of 20 universities and colleges across the nation in ... programs. This selection is the culmination of a ... Associate Dean Lisa Axe. Currently, some 43 percent ...
... out of the lab for a test drive with ... new way to develop possible future scenarios. James ... Center for Systems Integration and Sustainability (CSIS) and now ... London, has paired the relatively new use of agent-based ...
Cached Biology News:Hemophilia research gets NIH boost to a tune of $5.5 million 2Hemophilia research gets NIH boost to a tune of $5.5 million 3NSF funds NJIT's participation in program to retain engineering students 2Engaging land-use stakeholders is model behavior 2
(Date:4/24/2015)... 2015 PAREXEL International Corporation (NASDAQ: PRXL ... that Partnerships in Clinical Trials named PAREXEL,s Drew ... Innovator of the Year.  The honor recognizes Mr. Garty,s ... Perceptive MyTrials ® Data-Driven Monitoring solution. ... 2015 Partnership Awards in Boston , ...
(Date:4/23/2015)... April 23, 2015 /CNW/ - A new and innovative ... from North America,s largest ... won Silver in the "Sustainability, service" category of ... Brandcheck "Competitor Comparison" is a service that scores ... and Global peers. This benchmarking process shows clients ...
(Date:4/23/2015)... San Jose, California (PRWEB) April 23, 2015 ... – Predictive diagnostics refer to a series of ... such as cystic fibrosis, Lou Gehrig's disease, Huntington's ... beneficial in examining the gene composition and interaction ... of the disease as well as the response ...
(Date:4/23/2015)... Irvine, CA (PRWEB) April 23, 2015 ... research leader in Personalized Medicine, is excited to ... Medication Response profile . This profile assesses 62 ... and provide dosing information for commonly prescribed non-opioid ... gabapentin (brand name Neurontin), alprazolam (brand name Xanax) ...
Breaking Biology Technology:PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3
... Palatin Technologies,Inc. (Amex: PTN ) will announce ... 9, 2007 before the open of the U.S. financial,markets. ... live audio webcast,hosted by Palatin,s executive management team on ... of operations in greater detail and provide,an update on ...
... 5 Exelixis,Inc. (Nasdaq: EXEL ) today ... 30, 2007. Revenues for the quarter ended ... million for the comparable period in 2006. The ... due to revenue recognition,associated with new collaboration agreements ...
... patients in over 30 states on ... options since 1997, DEERFIELD, Ill., Nov. 5 ... Kidney Patient,Educator (KPE) program, an ambitious project that has ... treatment options to,nearly 80,000 kidney disease patients in over ...
Cached Biology Technology:Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 3Exelixis Announces Third Quarter 2007 Financial Results and Business Update 4Exelixis Announces Third Quarter 2007 Financial Results and Business Update 5Exelixis Announces Third Quarter 2007 Financial Results and Business Update 6Exelixis Announces Third Quarter 2007 Financial Results and Business Update 7Exelixis Announces Third Quarter 2007 Financial Results and Business Update 8Baxter Kidney Patient Education Program Celebrates Tenth Anniversary 2Baxter Kidney Patient Education Program Celebrates Tenth Anniversary 3Baxter Kidney Patient Education Program Celebrates Tenth Anniversary 4
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
Request Info...
... the rapid isolation of DNA from high melt ... the spin filter, centrifuge for 3 minutes, and ... is no need to melt agarose or use ... be used for buffer exchange, primer removal from ...
Request Info...
Biology Products: